Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Evelo Biosciences, Inc.: Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis
-Meaningful improvements over placebo on clinical scores, including new data released on key IGA endpoints-
-Initiation of Phase 2 trial of EDP1815 in atopic dermatitis expected in 3Q 2021-
CAMBRIDGE, Mass., April 20, 2021for all 24 patients in the cohort, which is re-iterated in the presentation, together with new data on the Investigator Global Assessment (IGA) score.
The primary endpoint of the Phase 1b trial was safety and tolerability. As previously disclosed, EDP1815 was well tolerated, with no treatment-related adverse events of moderate or severe intensity and no serious adverse events. The full results reinforce the data released on January 20, 2021, demonstrating that treatment with EDP1815 resulted in clinically meaningful improvements in both patient- and physician-reported outcomes. At the day 70 follow-up visit, 31% more EDP1815-trea
ABBVie today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ ™ in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs . 1 These data build on previously announced Phase 3 topline results showing that upadacitinib 15 mg and 30 …
ABBVie (NYSE: ABBV) today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ ™ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs). 1 These data build on previously announced Phase 3 topline results showing that upadacitinib 15 mg and 30 mg met the primary endpoint of ACR20 response at week 12 versus placebo as well as key secondary endpo
Share this article
NORTH CHICAGO, Ill., April 1, 2021 /PRNewswire/ AbbVie (NYSE: ABBV) today announced that the
New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ
™ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs).
1 These data build on previously announced Phase 3 topline results showing that upadacitinib 15 mg and 30 mg met the primary endpoint of ACR20 response at week 12 versus placebo as well as key secondary endpoints.
1 These data show upadacitinib s potential to improve clinical and radiographic outcomes for people with psoriatic arthritis, a complex and progressive autoimmune disease, said Thomas Hudson, MD, senior vice president, research and development, chief scientific officer, AbbVie. Ultimately, our goal is to help more patients achieve d
Ruxolitinib Cream for AD Is in Regulatory Home Stretch medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.